Recent advances in cell replacement therapies for the treatment of type 1 diabetes

Endocrinology

Volumn 156, Issue 1, 2015, Pages 8-15

  Cogger, Kathryn ^a   Nostro, Maria Cristina ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN;

CELL TRANSPLANTATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SYNTHESIS; LIFE EXPECTANCY; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PLURIPOTENT STEM CELL; REVIEW; XENOTRANSPLANTATION; DIABETES MELLITUS, TYPE 1; PANCREAS TRANSPLANTATION; PROCEDURES; TRENDS;

DIABETES MELLITUS, TYPE 1; HUMANS; ISLETS OF LANGERHANS TRANSPLANTATION; PANCREAS TRANSPLANTATION;

EID: 84919740508     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1691     Document Type: Review

References (76)

1. Matveyenko AV, Butler PC. Relationship between β-cell mass and diabetes onset. Diabetes Obes Metab. 2008;10(suppl 4):23-31
2. Pugliese A, Vendrame F, Reijonen H, Atkinson MA, Campbell- Thompson M, Burke GW. New insight on human type 1 diabetes biology: NPOD and nPOD-transplantation. Curr Diab Rep. 2014; 14(10):530
3. Vehik K, Ajami NJ, Hadley D, Petrosino JF, Burkhardt BR. The changing landscape of type 1 diabetes: Recent developments and future frontiers. Curr Diab Rep. 2013;13(5):642-650
4. Ludvigsson J. Why diabetes incidence increases-A unifying theory. Ann NY Acad Sci. 2006;1079:374-382
5. Skinner SJM,TanPLJ, Garkavenko O, MuzinaM,Escobar L, Elliott RB. Cell replacement therapy: The rationale for encapsulated porcine islet transplantation. In: Wagner D, ed. Type 1 Diabetes Compilations. Rijeka, Croatia: InTech; 2011
6. O'Connell PJ, Cowan PJ, Hawthorne WJ, Yi S, Lew AM. Transplantation of xenogeneic islets: Are we there yet? Curr Diab Rep. 2013
7. van der Windt DJ, Bottino R, Kumar G, et al. Clinical islet xenotransplantation: How close are we? Diabetes. 2012;61(12):3046-3055
8. Frank A, Deng S, Huang X, et al. Transplantation for type I diabetes: Comparison of vascularized whole-organ pancreas with isolated pancreatic islets. Ann Surg. 2004;240(4):631-640; discussion 640-633
9. Gruessner RW, Gruessner AC. The current state of pancreas transplantation. Nat Rev Endocrinol. 2013;9(9):555-562
10. Bellin MD, Barton FB, Heitman A, et al. Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes. Am J Transplant. 2012;12(6): 1576-1583
11. Pepper AR, Gala-Lopez B, Ziff O, Shapiro AM. Revascularization of transplanted pancreatic islets and role of the transplantation site. Clin Dev Immunol. 2013;2013:352315
12. Thompson DM, Meloche M, Ao Z, et al. Reduced progression of diabetic microvascular complications with islet cell transplantation compared with intensive medical therapy. Transplantation. 2011; 91(3):373-378
13. Korsgren O, Nilsson B, Berne C, et al. Current status of clinical islet transplantation. Transplantation. 2005;79(10):1289-1293
14. Scharp DW, Marchetti P. Encapsulated islets for diabetes therapy: History, current progress, and critical issues requiring solution. Adv Drug Deliv Rev. 2014;67-68:35-73
15. Scharp DW, Lacy PE, Santiago JV, et al. Insulin independence after islet transplantation into type I diabetic patient. Diabetes. 1990; 39(4):515-518
16. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.NEngl JMed. 2000;343(4):230-238
17. Ryan EA, Lakey JR, Rajotte RV, et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes. 2001;50(4):710-719
18. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006; 355(13):1318-1330
19. Group TDCaCTR. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin- dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group.NEngl J Med. 1993;329(14):977-986
20. Shapiro AM. State of the art of clinical islet transplantation and novel protocols of immunosuppression. Curr Diab Rep. 2011; 11(5):345-354
21. Calafiore R, Basta G. Clinical application of microencapsulated islets: Actual prospectives on progress and challenges. Adv Drug Deliv Rev. 2014;67-68:84-92
22. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-Analysis. Lancet. 2007; 370(9581):59-67
23. Kiberd BA, Rose C, Gill JS. Cancer mortality in kidney transplantation. Am J Transplant. 2009;9(8):1868-1875
24. Elliott RB, Living Cell Technologies. Towards xenotransplantation of pig islets in the clinic. Curr Opin Organ Transplant. 2011;16(2): 195-200
25. Basta G, Calafiore R. Immunoisolation of pancreatic islet grafts with no recipient's immunosuppression: Actual and future perspectives. Curr Diab Rep. 2011;11(5):384-391
26. Dolgin E. Encapsulate this. Nat Med. 2014;20(1):9-11
27. Insel RA, Deecher DC, Brewer J. Juvenile Diabetes Research Foundation: Mission, strategy, and priorities. Diabetes. 2012; 61(1):30-35
28. Thanos CG, Calafiore R, Basta G, et al. Formulating the alginatepolyornithine biocapsule for prolonged stability: evaluation of composition and manufacturing technique. J Biomed Mater Res A. 2007;83(1):216-224
29. Basta G, Montanucci P, Luca G, et al. Long-term metabolic and immunological follow-up of nonimmunosuppressed patients with type 1 diabetes treated with microencapsulated islet allografts: Four cases. Diabetes Care. 2011;34(11):2406-2409
30. Jansson L. The regulation of pancreatic islet blood flow. Diabetes Metab Rev. 1994;10(4):407-416
31. Lifson N, Kramlinger KG, Mayrand RR, Lender EJ. Blood flow to the rabbit pancreas with special reference to the islets of Langerhans. Gastroenterology. 1980;79(3):466-473
32. Barkai U, Weir GC, Colton CK, et al. Enhanced oxygen supply improves islet viability in a new bioartificial pancreas. Cell Transplant. 2013;22(8):1463-1476
33. Ludwig B, Rotem A, Schmid J, et al. Improvement of islet function in a bioartificial pancreas by enhanced oxygen supply and growth hormone releasing hormone agonist. Proc Natl Acad SciUSA. 2012; 109(13):5022-5027
34. Neufeld T, Ludwig B, Barkai U, et al. The efficacy of an immunoisolating membrane system for islet xenotransplantation in minipigs. PLoS One. 2013;8(8):e70150
35. Ludwig B, Zimerman B, Steffen A, et al. A novel device for islet transplantation providing immune protection and oxygen supply. Horm Metab Res. 2010;42(13):918-922
36. Ludwig B, Reichel A, Steffen A, et al. Transplantation of human islets without immunosuppression. Proc Natl Acad Sci USA. 2013; 110(47):19054-19058
37. Burman KD, Cunningham EJ, Klachko DM, Burns TW. Successful treatment of insulin resistance with dealaninated pork insulin (DPI). Mo Med. 1973;70(6):363-366
38. Graham ML, Schuurman HJ. The usefulness and limitations of the diabetic macaque model in evaluating long-term porcine islet xenograft survival. Xenotransplantation. 2013;20(1):5-17
39. Groth CG, Korsgren O, Tibell A, et al. Transplantation of porcine fetal pancreas to diabetic patients. Lancet. 1994;344(8934):1402-1404
40. Elliott RB, Escobar L, Tan PL, Muzina M, Zwain S, Buchanan C. Live encapsulated porcine islets from a type 1 diabetic patient 9.5 yr after xenotransplantation. Xenotransplantation. 2007;14(2):157-161
41. http://www.lctglobal.com. Living Cell Technologies. Last updated Nov 13, 2014
42. Calafiore R. Perspectives in pancreatic and islet cell transplantation for the therapy of IDDM. Diabetes Care. 1997;20(5):889-896
43. Calafiore R, Basta G, Luca G, et al. Transplantation of pancreatic islets contained in minimal volume microcapsules in diabetic high mammalians. Ann NY Acad Sci. 1999;875:219-232
44. Elliott RB, Escobar L, Garkavenko O, et al.Noevidence of infection with porcine endogenous retrovirus in recipients of encapsulated porcine islet xenografts. Cell Transplant. 2000;9(6):895-901
45. Garkavenko O, Croxson MC, Irgang M, Karlas A, Denner J, Elliott RB. Monitoring for presence of potentially xenotic viruses in recipients of pig islet xenotransplantation. J Clin Microbiol. 2004; 42(11):5353-5356
46. Paradis K, Langford G, Long Z, et al. Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. The XEN 111 Study Group. Science. 1999; 285(5431):1236-1241
47. Hermida-Prieto M, Domenech N, Moscoso I, et al. Lack of cross- species transmission of porcine endogenous retrovirus (PERV) to transplant recipients and abattoir workers in contact with pigs. Transplantation. 2007;84(4):548-550
48. Thompson P, Badell IR, Lowe M, et al. Islet xenotransplantation using gal-deficient neonatal donors improves engraftment and function. Am J Transplant. 2011;11(12):2593-2602
49. Cozzi E, White DJ. The generation of transgenic pigs as potential organ donors for humans. Nat Med. 1995;1(9):964-966
50. van der Windt DJ, Bottino R, Casu A, et al. Long-term controlled normoglycemia in diabetic non-human primates after transplantation with hCD46 transgenic porcine islets. Am J Transplant. 2009; 9(12):2716-2726
51. Ayares D, Phelps C, Vaught T, et al. Multi-transgenic pigs for vascularized pig organ xenografts. Xenotransplantation. 2011;18:269
52. Ayares D, Phelps C, Vaught T, et al. Multi-transgenic pigs for xenoislet transplantation. Xenotransplantation. 2013;20:46
53. Brady JL, Sutherland RM, Hancock M, et al. Anti-CD2 producing pig xenografts effect localized depletion of human T cells in a huSCID model. Xenotransplantation. 2013;20(2):100-109
54. D'Amour KA, Bang AG, Eliazer S, et al. Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol. 2006;24(11):1392-1401
55. Nostro MC, Sarangi F, Ogawa S, et al. Stage-specific signaling through TGFβ family members and WNT regulates patterning and pancreatic specification of human pluripotent stem cells. Development. 2011;138(5):861-871
56. Rezania A, Riedel MJ, Wideman RD, et al. Production of functional glucagon-secreting β-cells from human embryonic stem cells. Diabetes. 2011;60(1):239-247
57. Kunisada Y, Tsubooka-Yamazoe N, Shoji M, Hosoya M. Small molecules induce efficient differentiation into insulin-producing cells from human induced pluripotent stem cells. Stem Cell Res. 2012;8(2):274-284
58. Hrvatin S, O'Donnell CW, Deng F, et al. Differentiated human stem cells resemble fetal, not adult, β cell. Proc Natl Acad Sci USA. 2014;111(8):3038-3043
59. Micallef SJ, Li X, Schiesser JV, et al. INS(GFP/w) human embryonic stem cells facilitate isolation of in vitro derived insulin-producing cells. Diabetologia. 2012;55(3):694-706
60. Basford CL, Prentice KJ, Hardy AB, et al. The functional and molecular characterisation of human embryonic stem cell-derived insulin- positive cells compared with adult pancreatic β cell. Diabetologia. 2012;55(2):358-371
61. Kroon E, Martinson LA, Kadoya K, et al. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol. 2008;26(4):443-452
62. Herrera PL. Adult insulin- and glucagon-producing cells differentiate from two independent cell lineages. Development. 2000; 127(11):2317-2322
63. Riedel MJ, Asadi A, Wang R, Ao Z, Warnock GL, Kieffer TJ. Immunohistochemical characterisation of cells co-producing insulin and glucagon in the developing human pancreas. Diabetologia. 2012;55(2):372-381
64. Jeon J, Correa-Medina M, Ricordi C, Edlund H, Diez JA. Endocrine cell clustering during human pancreas development. J Histochem Cytochem. 2009;57(9):811-824
65. Rezania A, Bruin JE, Riedel MJ, et al. Maturation of human embryonic stem cell-derived pancreatic progenitors into functional islets capable of treating pre-existing diabetes in mice. Diabetes. 2012; 61(8):2016-2029
66. Kelly OG, Chan MY, Martinson LA, et al. Cell-surface markers for the isolation of pancreatic cell types derived from human embryonic stem cells. Nat Biotechnol. 2011;29(8):750-756
67. Rezania A, Bruin JE, Xu J, et al. Enrichment of human embryonic stem cell-derived NKX6.1-expressing pancreatic progenitor cells accelerates the maturation of insulin-secreting cells in vivo. Stem Cells. 2013;31(11):2432-2442
68. Schulz TC, Young HY, Agulnick AD, et al. A scalable system for production of functional pancreatic progenitors from human embryonic stem cells. PLoS One. 2012;7(5):e37004
69. Bruin JE, Rezania A, Xu J, et al. Maturation and function of human embryonic stem cell-derived pancreatic progenitors in macroencapsulation devices following transplant into mice. Diabetologia. 2013; 56(9):1987-1998
70. http://viacyte.com/press-releases/viacyte-inc-Announces-fdaacceptance-of-ind-to-commence-clinical-trial-of-vc-01-candidatecell-replacement-therapy-for-type-1-diabetes/. Viacyte. Published Aug 19th, 2014
71. Cheng X, Ying L, Lu L, et al. Self-renewing endodermal progenitor lines generated from human pluripotent stem cells. Cell Stem Cell. 2012;10(4):371-384
72. Li K, Zhu S, Russ HA, et al. Small molecules facilitate the reprogramming of mouse fibroblasts into pancreatic lineages. Cell Stem Cell. 2014;14(2):228-236
73. Rezania A, Bruin JE, Arora P, et al. Reversal of diabetes with insulinproducing cells derived in vitro from human pluripotent stem cells. Nat Biotechnol. 2014;32(11):1121-1133
74. Pagliuca FW, Millman JR, GürtlerM,et al. Generation of functional human pancreatic β cell in vitro. Cell. 2014;159(2):428-439
75. Tibell A, Rafael E, Wennberg L, et al. Survival of macroencapsulated allogeneic parathyroid tissue one year after transplantation in nonimmunosuppressed humans. Cell Transplant. 2001;10(7):591-599
76. Kontos S, Kourtis IC, Dane KY, Hubbell JA. Engineering antigens for in situ erythrocyte binding induces T-cell deletion. Proc Natl Acad Sci USA. 2013;110(1):E60-E68.